Literature DB >> 33243732

[Association of JMJD3, MMP-2 and VEGF expressions with clinicopathological features of invasive ductal breast carcinoma].

Xiaoyan Xu1, Jianjun Wang1, Chen Yan1, Yingli Men2, Huang Jiang1, Huijuan Fang1, Xianwei Xu1, Jinhua Yang1.   

Abstract

OBJECTIVE: To examine the expressions of JMJD3, matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in invasive ductal breast carcinoma, their association with the clinicopathological features of the patients and the effect of JMJD3 overexpression on proliferation and MMP-2 and VEGF expressions in breast cancer cells.
METHODS: The protein and mRNA expressions of JMJD3, MMP-2, and VEGF in invasive ductal breast carcinoma and paired adjacent tissues were detected by immunohistochemistry and RT-PCR, respectively, and their correlation with the clinicopathological characteristics of the patients was analyzed. Kaplan-Meier survival analysis was used to evaluate the correlation of JMJD3, MMP-2 and VEGF expression levels with the survival of the patients. In breast cancer MDA-MB-231 cells transfected with a JMJD3-expression plasmid, the expression of Ki67 was examined immunohistochemically, the cell proliferation was assessed with CCK8 assay, and the mRNA expressions of MMP-2 and VEGF were detected with RT-PCR.
RESULTS: Breast cancer tissues had significantly lower JMJD3 expression and higher MMP-2 and VEGF expressions at both the mRNA and protein levels than the adjacent tissue (P < 0.05). The positivity rates of JMJD3, MMP-2 and VEGF in breast cancer tissues were significantly correlated with tumor diameter, differentiation, TNM stage, lymph node metastasis, and molecular subtypes (P < 0.05). KaplanMeier analysis showed that JMJD3 expression level was positively while MMP-2 and VEGF were inversely correlated with the disease-free survival time of the patients (P < 0.05). Cox regression analysis identified JMJD3, MMP-2, VEGF and tumor differentiation as independent prognostic factors of breast cancer. Spearman correlation analysis suggested a negative correlation of JMJD3 with MMP2 (r=-0.569, P < 0.05) and VEGF (r=-0.533, P < 0.05) and a positive correlation between MMP2 and VEGF (r=0.923, P < 0.05). In MDA-MB-231 cells, overexpression of JMJD3 inhibited the proliferation of MDA-MB-231 cells and the expression of MMP-2 and VEGF.
CONCLUSIONS: The expressions of JMJD3, MMP-2 and VEGF in invasive ductal breast carcinoma are closely correlated to tumor proliferation, invasion, metastasis and prognosis and can be used for prognostic evaluation of breast cancer.

Entities:  

Keywords:  JMJD3; clinicopathological features; invasive ductal carcinoma of breast; matrix metalloproteinase-2; vascular endothelial growth factor

Mesh:

Substances:

Year:  2020        PMID: 33243732      PMCID: PMC7704386          DOI: 10.12122/j.issn.1673-4254.2020.11.09

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  22 in total

1.  VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation.

Authors:  Anna Fantozzi; Dorothea C Gruber; Laura Pisarsky; Chantal Heck; Akiko Kunita; Mahmut Yilmaz; Nathalie Meyer-Schaller; Karen Cornille; Ulrike Hopfer; Mohamed Bentires-Alj; Gerhard Christofori
Journal:  Cancer Res       Date:  2014-01-10       Impact factor: 12.701

2.  Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Hee Jung Kim; Chan-il Park; Byeong Woo Park; Hy-de Lee; Woo Hee Jung
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

3.  Aberrant JMJD3 Expression Upregulates Slug to Promote Migration, Invasion, and Stem Cell-Like Behaviors in Hepatocellular Carcinoma.

Authors:  Bo Tang; Guangying Qi; Fang Tang; Shengguang Yuan; Zhenran Wang; Xingsi Liang; Bo Li; Shuiping Yu; Jie Liu; Qi Huang; Yangchao Wei; Run Zhai; Biao Lei; Hongping Yu; Stephen Tomlinson; Songqing He
Journal:  Cancer Res       Date:  2016-09-20       Impact factor: 12.701

Review 4.  Breast cancer in China.

Authors:  Lei Fan; Kathrin Strasser-Weippl; Jun-Jie Li; Jessica St Louis; Dianne M Finkelstein; Ke-Da Yu; Wan-Qing Chen; Zhi-Ming Shao; Paul E Goss
Journal:  Lancet Oncol       Date:  2014-06       Impact factor: 41.316

5.  The Prognostic Significance of Histone Lysine Demethylase JMJD3/KDM6B in Colorectal Cancer.

Authors:  Ryuma Tokunaga; Yasuo Sakamoto; Shigeki Nakagawa; Keisuke Miyake; Daisuke Izumi; Keisuke Kosumi; Katsunobu Taki; Takaaki Higashi; Yu Imamura; Takatsugu Ishimoto; Masaaki Iwatsuki; Yoshifumi Baba; Yuji Miyamoto; Naoya Yoshida; Eiji Oki; Masayuki Watanabe; Hideo Baba
Journal:  Ann Surg Oncol       Date:  2015-09-28       Impact factor: 5.344

6.  GSKJ4, A Selective Jumonji H3K27 Demethylase Inhibitor, Effectively Targets Ovarian Cancer Stem Cells.

Authors:  Hirotsugu Sakaki; Masashi Okada; Kenta Kuramoto; Hiroyuki Takeda; Hikaru Watarai; Shuhei Suzuki; Shizuka Seino; Manabu Seino; Tsuyoshi Ohta; Satoru Nagase; Hirohisa Kurachi; Chifumi Kitanaka
Journal:  Anticancer Res       Date:  2015-12       Impact factor: 2.480

7.  Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.

Authors:  Sha Li; Lu Wang; Yue Meng; Yanli Chang; Jianjun Xu; Qingyun Zhang
Journal:  Oncotarget       Date:  2017-06-20

8.  The crucial role of SRPK1 in IGF-1-induced EMT of human gastric cancer.

Authors:  Hong Wang; Chunlei Wang; Wenling Tian; Yanfen Yao
Journal:  Oncotarget       Date:  2017-08-07

9.  A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2.

Authors:  Marine Daures; Mouhamed Idrissou; Gaëlle Judes; Khaldoun Rifaï; Frédérique Penault-Llorca; Yves-Jean Bignon; Laurent Guy; Dominique Bernard-Gallon
Journal:  Oncotarget       Date:  2018-05-04

10.  The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells.

Authors:  Aixia Sui; Yongbing Xu; Yitong Li; Qilu Hu; Zeyang Wang; Hongtao Zhang; Junjie Yang; Xiaoqiang Guo; Wenqing Zhao
Journal:  Oncotarget       Date:  2017-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.